Autolus AUCATZYL Sales Surge 95% — Its Annual Outlook Now Reaches The Former Ceiling
Manufacturing margins improved, but the company moved its first multiple-sclerosis data presentation to October 2027.
Autolus Therapeutics, which sells the leukemia cell therapy AUCATZYL, grew third-quarter product sales 95% to $41.2 million, from $21.1 million a year earlier, according to Tuesday's SEC filing and accompanying results. It now expects annual AUCATZYL sales to reach or exceed $150 million, the top of its previous forecast.
More Centers, Cheaper Manufacturing
Autolus attributed the sales increase to demand from existing treatment centers and expansion into new ones, with U.K. sales adding to the growth. Its U.S. network now comprises 90 authorized centers. Product sales for the first nine months reached $113.1 million, up 122% from a year earlier.
Production costs fell to $17.9 million from $28.6 million a year earlier. Autolus kept 57% of sales after those costs, compared with 55% in the second quarter, crediting higher volumes, manufacturing efficiencies and lower inventory reserves and write-offs.
The manufacturing turnaround stretches beyond this quarter: gross margin was negative 9% in the fourth quarter of 2025 and turned positive at 6% in the first quarter of 2026. Autolus expects an eventual gross margin of 65%–70%.
AUCATZYL uses genetically reprogrammed patient T cells to treat adults whose B-cell precursor acute lymphoblastic leukemia has returned or resisted treatment. It received FDA approval on November 8, 2024, and conditional U.K. and EU authorizations in 2025. Autolus manufactures it at its Nucleus facility in Stevenage, U.K.; treatment is restricted to authorized specialist centers, and it is available through the National Health Service in England and Wales.
Losses Narrow, Financing Adds Cash
Autolus' quarterly net loss narrowed to $55.1 million from $79.1 million, or $0.21 rather than $0.30 per ordinary share. Its operating loss fell to $43.5 million from $71.6 million.
Research spending increased to $30.9 million from $27.9 million, mainly because of clinical manufacturing supply costs, the company said. Selling and administrative spending declined to $35.9 million from $36.3 million.
Cash and marketable securities totaled $248.4 million at September 30, compared with $201.6 million at June 30. Autolus attributed the increase primarily to financing from Perceptive Advisors. It expects current and projected resources—including anticipated product revenue and $100 million from the Perceptive credit facility—to support operations into the second quarter of 2028.
Multiple-Sclerosis Data Moves To 2027
Autolus moved its first progressive multiple-sclerosis data presentation to October 2027 from the first quarter of 2027. Specialists at the late-October ACTRIMS/ECTRIMS meeting recommended longer observation to assess clinical benefit. The company expects at least 12 months of follow-up for the initial 12 patients and data from up to 24 patients overall.
Autolus Chief Executive Officer Christian Itin said, “We look forward to autoimmune program data presentations at upcoming key medical meetings.” A lupus update is scheduled for Tuesday at the American College of Rheumatology annual meeting, covering up to 25 months of adult follow-up and at least three months for adolescents.
The company expects pediatric leukemia results by year-end 2027 and lupus-nephritis results in 2028. The lupus-nephritis trial is enrolling across five countries; the FDA granted obe-cel a designation intended to accelerate regenerative-medicine development and review for lupus and lupus nephritis on September 9, 2026.
The next scheduled initial readout is AUTO8's early-stage trial in light-chain amyloidosis, with results expected on December 12, 2026.
